Titan Pharmaceuticals Inc

Titan Pharmaceuticals — Investor Presentation (November 2016)

24 slides from Titan Pharmaceuticals's investor presentation, Nov 16, 2016

  1. Slide 1: Titan Pharmaceuticals Corporate Presentation

    TITAN PHARMACEUTICALS CORPORATE PRESENTATION SUNIL BHONSLE NOVEMBER 2016 © 2016 TITAN PHARMACEUTICALS INC. NASDAQ:TTNP

  2. Slide 2: Forward-Looking Statements

    FORWARD - LOOKING STATEMENTS The presentation may contain “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . Reference is made in particular to the description of our plans and objectives for futur

  3. Slide 3: Company Snapshot

    COMPANY SNAPSHOT 3 • Focus on proprietary therapeutics for select chronic diseases • ProNeura TM drug delivery platform provides long - term, continuous, non - fluctuating medication levels • Probuphine® (buprenorphine) implant – six - month maintenance treatment of opioid addiction • FDA approval M

  4. Slide 4: Opioid Addiction: An Epidemic

    OPIOID ADDICTION: AN EPIDEMIC • Increasingly recognized as a global epidemic by world health authorities • Primary, chronic disease of brain reward, motivation, memory and neurobiological circuitry • Characterized by cravings, accompanied by a lack of impulse control, cycles of relapse and remission

  5. Slide 5: Opioid Addiction: Treatment Overview

    OPIOID ADDICTION: TREATMENT OVERVIEW 5 • Buprenorphine pharmacology makes it an effective, safer, and more convenient treatment option • Controls withdrawal symptoms and cravings without inducing opioid euphoria in patients • Convenient outpatient treatment allows take - home medication, unlike meth

  6. Slide 6: Probuphine (Buprenorphine) Implant

    PROBUPHINE® (BUPRENORPHINE) IMPLANT 6 • Implant contains 80 mg of buprenorphine HCl uniformly distributed throughout the ethylene vinyl acetate co - polymer (EVA) matrix • No reservoir, therefore no risk of drug dumping EVA POLYMER BUPRENORPHINE PROBUPHINE BLENDED & EXTRUDED • Probuphine recognized

  7. Slide 7: Probuphine Administration

    PROBUPHINE® ADMINISTRATION 7 • Inserted subdermally in the inner side of the upper arm by a certified health care provider • Drug is released continuously into patient's body through the process of dissolution • Results in a stable level of medication in the blood, avoiding peaks and troughs of oral

  8. Slide 8: Probuphine (Buprenorphine) Implant

    PROBUPHINE® (BUPRENORPHINE) IMPLANT 8 Probuphine® is the first and only FDA - approved maintenance treatment for opioid dependence that provides non - fluctuating blood levels of buprenorphine around - the - clock for a period of six months EFFICACY Effective in reducing illicit opioid use SAFETY No

  9. Slide 9: Probuphine: Risk Evaluation & Mitigation Strategy

    PROBUPHINE®: RISK EVALUATION & MITIGATION STRATEGY 9 • Training and Certification – Providers who prescribe and implant Probuphine will: • A ttend Live Training: Lecture and Practicum • C omplete the Probuphine REMS P rogram K nowledge Assessment • B e enrolled in the Probuphine REMS program • Provi

  10. Slide 10: Probuphine: Commercialization

    PROBUPHINE®: COMMERCIALIZATION 10 Partnership with Braeburn Pharmaceuticals, Inc. for development and commercialization of P robuphine in U.S. and Canada* • Milestone payments: • Upfront : $15.75 million • Approval Milestone: $15 million • Sales Milestones: $165 million • Tiered Royalties on net sal

  11. Slide 11: Probuphine: U.S. Certified Health Care Providers

    PROBUPHINE®: U.S. CERTIFIED HEALTH CARE PROVIDERS 11 Information on Probuphine available at www.ProbuphineREMS.com

  12. Slide 12: Probuphine: Ex-U.S. Partnering Plans

    PROBUPHINE®: EX - U.S. PARTNERING PLANS 12 • Pursuing ex - U.S. opportunities in opioid addiction treatment • Due diligence by interested companies in select regions is in progress • Scientific and regulatory discussions with select European countries scheduled in late fourth quarter of 2016 • Oppor

  13. Slide 13: ProNeura: Adding Value Beyond Probuphine

    PRONEURA: ADDING VALUE BEYOND PROBUPHINE® 13 • Long - term drug delivery technology validated through the Probuphine® program • Potential for the treatment of select chronic diseases for which low dose, long - term delivery and stable drug levels may offer advantages over other forms of administrati

  14. Slide 14: Parkinson's Disease Overview

    PARKINSON’S DISEASE OVERVIEW • Characterized by the loss of dopamine, which alters activity in the brain region impacting movement and motor function • Treated with drugs designed to replace or mimic dopamine in the brain • After several years of treatment , these drugs lose benefit and trigger seri

  15. Slide 15: Parkinson's Disease – Therapeutics Market

    PARKINSON’S DISEASE – THERAPEUTICS MARKET 15 * GlobalData; **Parkinson’s Action Network, National Center for Health Statistics; “The Current and Projected Economic Burden of Parkinson’s Disease in the United States” Movement Disorders, March 2013 Based on information from Titan and other sources bel

  16. Slide 16: ProNeura Parkinson's Disease Program

    PRONEURA TM PARKINSON’S DISEASE PROGRAM 16 • Ropinirole (Requip®), a dopamine agonist marketed by GSK for PD • Evaluated in a Parkinsonian animal model using ProNeura T M drug delivery platform • Results presented in June 2015 - 19th International Congress of Parkinson's Disease and Movement Disorde

  17. Slide 17: Hypothyroidism Disease Overview

    HYPOTHYROIDISM DISEASE OVERVIEW • Thyroid gland does not make enough thyroid hormone to meet body’s need • Typical treatment consists of synthetic prohormone thyroxine (T4) given orally once a day, which is converted by the body to the active triiodothyronine (T3) • Oral T3 treatment is effective, b

  18. Slide 18: ProNeura Hypothyroidism Program Status

    PRONEURA TM HYPOTHYROIDISM PROGRAM STATUS 18 • Completed initial formulation development of the implant and conducted in - vitro and in - vivo drug release studies to further define implant formulation • In - vivo non - clinical studies in progress evaluating implant formulations for drug release ch

  19. Slide 19: Titan ProNeura Product Pipeline

    TITAN PRONEURA PRODUCT PIPELINE 19 CANDIDATE INDICATION DEVELOPMENT STAGE Probuphine ® Opioid Addiction Ropinirole Implant Parkinson’s Disease T3 Implant Hypothyroidism PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET

  20. Slide 20: Titan Executive Management

    TITAN EXECUTIVE MANAGEMENT 20 • Marc Rubin, M . D . Executive Chairman & Director • 9 years with Titan • Former Head of Global R&D and member of the Board of Management at Bayer Pharma • Executive R&D and commercial responsibilities at GSK for 13 years • 25 years in the pharmaceutical industry follo

  21. Slide 21: Titan Pharma Summary

    TITAN PHARMA SUMMARY • ProNeura ™ - Unique and compelling long - term drug delivery platform • Probuphine ® - Only product on market to provide six month, continuous, non - fluctuating blood levels of buprenorphine for maintenance treatment of opioid addiction • Attractive U . S . partnership in pla

  22. Slide 22: Thank You. Questions?

    THANK YOU. QUESTIONS? © 2016 TITAN PHARMACEUTICALS INC. NASDAQ:TTNP

  23. Slide 23: Probuphine: Risk Evaluation & Mitigation Strategy

    PROBUPHINE®: RISK EVALUATION & MITIGATION STRATEGY 23

  24. Slide 24: Medical Specialties of REMS-Trained Healthcare Providers

    Medical Specialties of REMS - Trained Healthcare Providers 24 582 236 199 63 172 144 79 51 45 8 5 6 79 6 1 81 98 433 4 47 5 2 16 3 0 250 500 750 Prescriber only Implanter only Dual role REMS: Risk Evaluation and Mitigation Strategy Number of trained providers

Titan Pharmaceuticals — Investor Presentation (November 2016) on 6ix